387825-03-8

Basic information

• Product Name: Salclobuzic acid
• Synonyms: Salclobuzic acid;Butanoic acid, 4-[(4-chloro-2-hydroxybenzoyl)aMino]-
• CAS NO: 387825-03-8
• Molecular Formula: C₁₁H₁₂ClNO₄
• Molecular Weight: 257.67028
• Mol File: 387825-03-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Salclobuzic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Salclobuzic acid(387825-03-8)
• EPA Substance Registry System: Salclobuzic acid(387825-03-8)

Safety Data

• Hazardous Substances Data: 387825-03-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Salclobuzic acid is used as an antineoplastic agent for its potential to inhibit the growth of tumor cells. It functions as a chelating agent, which may contribute to its antineoplastic properties.
Used in Antituberculosis Applications:
Salclobuzic acid is used as an antituberculosis agent for its potential to boost the efficacy of certain antibiotics in treating tuberculosis. Its chelating properties may also play a role in enhancing the effectiveness of these antibiotics.

Upstream product

• 5106-98-9 4-chlorosalicylic acid 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 31544-40-8 7-chloro-benzo[e][1,3]oxazine-2,4-dione 
• 6937-16-2 ethyl γ-aminobutyrate hydrochloride 
• 530-62-1 1,1'-carbonyldiimidazole 

Relevant articles and documents

4-CNAB and preparation method thereof

The invention discloses 4-CNAB and a preparation method thereof, and belongs to the field of drug preparation. According to the technical scheme, the preparation method comprises the following steps:S1, adding dichloromethane into 4-chlorosalicylic acid, adding sodium bentonite and N, N-carbonyl diimidazole, then adding ethyl 4-aminobutyrate hydrochloride, dropwise adding triethylamine, adding adiluted hydrochloric acid solution, adjusting the pH value to 4.5-5, performing suction filtration, collecting filtrate, sequentially extracting with dilute ammonia water, pure water and a saturated sodium chloride solution, and concentrating an organic phase to obtain an intermediate I; S2, dissolving the intermediate I with a sodium hydroxide solution, dropwise adding a dilute hydrochloric acidsolution, adjusting the pH value to 4.5-5, separating out a product, and carrying out suction filtration and drying to obtain free acid; S3, dissolving free acid with isopropanol, adding a sodium hydroxide solution, after a reaction is carried out for 1 h, supplementing isopropanol and reacting for 1-2 h, performing suction filtration and drying to obtain 4-CNAB. The yield of each step is high, the product purity is good, and the salified product is easy for suction filtration.

Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate

The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.

Compounds and compositions for delivering active agents

Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provide as well.

Oral insulin therapy

A method of attenuating the undesirable incidence of diseases associated with chronic dosing of insulin is provided whereby the oral administration to a patient of insulin along with a suitable delivery agent that facilitates the absorption of insulin from the gastrointestinal tract of the patient in a therapeutically effective amount, for treatment of diabetes. Also disclosed are pharmaceutical dosage forms for oral administration to a patient for the treatment of diabetes, comprising insulin and a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and that result in a lower incidence of vascular diseases associated with the repeated administration of insulin.